VYNDAQEL caps moll 61 mg 30 pce

7680675180011 CH-67518 N07XX08 01.99.0.

Active substances:

VYNDAQEL caps moll 61 mg 30 pce
VYNDAQEL caps moll 61 mg 30 pce
VYNDAQEL caps moll 61 mg 30 pce
1 / 3
google

Details

Product number
6751801
CPT
-
Packaging group
30
Unit
Kapsel(n)
Composition
tafamidisum 61 mg, macrogolum 400, polysorbatum 20, povidonum K 90, E 321, Kapselhülle: gelatina, glycerolum, sorbitolum liquidum partim deshydricum corresp. sorbitolum max. 44 mg, E 172 (rubrum), Drucktinte: macrogolum 400, polyvinylis acetas phtalas, E 171, propylenglycolum, pro capsula.

Articles (1)

Vyndaqel 61 mg, Weichkapseln
Weichkapseln
30
View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
tafamidisum
61.0 MG Substance Wirkstoff (Principe actif)
macrogolum 400
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
polysorbatum 20
- Substance HNIDK
povidonum K 90
- Substance HNIDK
E 321
- Substance ANTOX
gelatina
- Substance HNIDK
glycerolum
- Substance HNIDK
sorbitolum liquidum partim deshydricum
- Substance HNIDK
sorbitolum
- Substance HBESI
E 172 (rubrum)
- Substance FTODK
macrogolum 400
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
polyvinylis acetas phtalas
- Substance HNIDK
E 171
- Substance FNIDK
propylenglycolum
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)

Reimbursement information

Public price
CHF 9013.25
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/12/2021

Authorization holder

Pfizer AG

8052 Zürich

Authorization information

Swissmedic authorization number
67518
Drug name
Vyndaqel 61 mg, Weichkapseln
Galenic form
KAPWE
ATC Code
N07XX08
Authorization status
Z
Dispensation category
B
First authorization
05/03/2020
Authorization expiration date
31/12/9999
IT number
01.99.0.
Domain
Human medicine
Field of application
Behandlung der Transthyretin-Amyloidose bei erwachsenen Patienten mit Wildtyp- oder hereditärer Kardiomyopathie

Packaging details

Description (FR)
VYNDAQEL caps moll 61 mg 30 pce
Description (DE)
VYNDAQEL Weichkaps 61 mg 30 Stk
Market launch
05/03/2020
Narcotic (BTM)
No
Buy us a coffee Explore the data